Inhibition of progression of erythroleukemia induced by Friend virus in BALB/c mice by natural products - Berberine, curcumin and picroliv

Journal of Experimental Therapeutics and Oncology

Volumn 7, Issue 4, 2008, Pages 275-284

  Harikumar, Kuzhuvelil B ^a,b   Kuttan, Girija ^a   Kuttan, Ramadasan ^a  

^a AMALA CANCER RESEARCH CENTRE   (India)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Berberine; Curcumin; Erythroleukemia; Friend virus; Picroliv

Indexed keywords

BERBERINE; CURCUMIN; ERYTHROPOIETIN; GAMMA INTERFERON RECEPTOR; KUTKIN; NATURAL PRODUCT; PROTEIN BCL 2; PROTEIN P53; RAF PROTEIN; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; ERYTHROLEUKEMIA; FRIEND LEUKEMIA VIRUS; GENE EXPRESSION; HISTOPATHOLOGY; LIFESPAN; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BERBERINE; BIOLOGICAL PRODUCTS; CINNAMATES; CURCUMIN; DISEASE PROGRESSION; FRIEND MURINE LEUKEMIA VIRUS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSIDES; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; URIC ACID; VANILLIC ACID;

EID: 58649117530     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Butel JS. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 21: 405-426, 2000.
2. Ben-David Y, Bernstein A.. Friend virus induced erythroleukemia and the multistage nature of cancer. Cell 66: 831-834, 1991.
3. Ruscetti SK. Deregulation of erythropoiesis by the Friend spleen locus forming virus. Int J Biochem Cell Biol 31: 1089-1109, 1999.
4. Ney PA, D'Andrea AD. Friend leukemia revisited. Blood 96: 3675-3680, 2000.
5. Lee CR, Cervi D, Truong AHL, Li YJ, Sarkar A, Ben-David Y. Friend virus-induced erythroleukemia: a unique and well defined mouse model for the development of leukemia. Anticancer Res 23: 2159-2166, 2003.
6. Zhang F, Yang B, Gu H, Chen XB, Zhong Z, Cheng Z. Effects of tacrolimus on infection of Friend murine erythroleukemia virus to Fv-4 gene heterozygous mice. Acta Pharmacol Sin 25: 208-212, 2004.
7. Kuttan R, Bhanumathy P, Nirmala K, George MC. Potential anticancer activity of Turmeric (Curcuma longa). Cancer Lett 9: 197-202, 1985.
8. Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH. Inhibitory effects of dietary Curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 54: 5841-5847, 1994.
9. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of Curcumin: Preclinical and clinical studies. Anticancer Res 23: 363-398, 2003.
10. Kuttan G, Kumar KBH, Guruvayoorappan C, Kuttan R. Antitumor, anti-invasion and anti-metastatic effects of curcumin. Adv Exp Med Biol 595: 173-184, 2007.
11. Hsu CH, Cheng A L. Clinical studies with curcumin. Adv Exp Med Biol 595: 471-480, 2007.
12. Mazumder A, Raghavan K, Weinstein J, Kohn KW, Pommier Y.Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem. Pharmacol 49: 1165-1170, 1995.
13. Dhawan BN. Picroliv- A new hepatoprotrctive agent from an Indian medicinal plant, Picrorhiza kurroa. Med Chem Res 5: 595-605, 1995.
14. Seth P, Sundar SV, Seth RK, Sindhu GS, Kulshreshtra DK, Maheswari RK. Picroliv modulates antioxidant status and down-regulates APl transcription factor after hemorrhage and resuscitation. Shock 19: 169-175, 2003.
15. Mehrotra R, Rawat S, Kulshreshtha DK, Patnaik GK., Dhawan BN. In vitro studies on the effect of certain natural products against hepatitis B virus. Indian J Med Res 92: 133-138, 1990.
16. Rajeshkumar NV, Kuttan R. Inhibition of N-nitrosodiethylamine-induced hepatocarcinogenesis by Picroliv. J Exp Clin Cancer Res 19: 459-465, 2000.
17. Anis KV, Kuttan G, Kuttan R. Role of Berberine as an adjuant response modifier during tumour therapy in mice. Pharm Pharmacol Commun 5: 697-700, 1999.
18. Hayashi K, Minoda K, Nagaoka Y, Hayashi T, Uesato S. Antiviral activity of Berberine and related compounds against human cytomegalovirus. Bioorg Med Chem Lett 17: 1562-1524, 2007.
19. Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by Berberine in rats and mice. J Pharm Pharmacol 53: 763-768, 2001.
20. Cervi D, Shaked Y, Haeri M, Usenko T, Lee CR, Haigh JJ, Nagy A, Kerbel RS, Yefenof E, Ben-David Y. Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia. Blood 109: 2139-2146, 2007.
21. Swirsky D, and Bain BJ. Erythrocyte and leucocyte cytochemistry-leukemia classification. In ewis SM, Bain BJ and Bates I (ed.) Dacie and Lewis Practical Haematology 9/e. Churchill Livingstone, London, pp 282-285, 2001.
22. Chomczynski P, Sacchi N. Single-step method for RNA isolation by acid guanidinium thiocynate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
23. Chomczynski P, Sacchi N. The single-step method for RNA isolation by acid guanidinium thiocynate-phenol-chloroform extraction: twenty-something years on. Nature Protocols 1: 581-585, 2006.
24. Friend C. Cell-free transmission in adult swiss mice of a disease having the character of a leukemia. J Exp Med 105: 307-318, 1957.
25. Subramanian A, Hegde S, Correll PH, Paulson R F. Mutation of the Lyn tyrosine kinase delays the progression of Friend virus induced erythroleukemia without affecting susceptibility. Leukemia Res. 30: 1141-1149, 2006.
26. Wong KS, Li YJ, Howard J, Ben-David Y. Loss of p53 in FMuLv induced erythroleukemias accelerates the acquisition of mutational events that confers immortality and growth factor independence. Oncogene 18: 5525-5534, 1999.
27. Howard JC, Li Q, Chu W, Zochodne B, Kapoor M, Ung Y, Rosen K , Ben-David Y., Bcl-2 expression in F-MuLv-induced erythroleukemias: a role for the anti-apoptotic action of Bcl-2 during tumor progression. Oncogene 20: 2291-2300, 2001.
28. Li YJ, Higgins RR, Pak BJ, Shivdasani RA, Ney PA, Archer M, Ben-David Y., p45NFE2 is a negative regulator of erythroid proliferation which contributes to the progression of Friend virus induced erythroleukemias. Mol Cellular Biol 21: 73-80, 2001.
29. Frickson-miller CL, Pelus LM, Lord KA. Signaling induced by erythropoietin and stem cell factor in ut-7/epo cells: transient versus sustained proliferation. Stem Cells 18: 366-373, 2000.
30. Howard JC, Berger L, Bani MR, Hawley R, Ben-David Y. Activation of the erythropoietin gene in majority of F-MuLv-induced erythroleukemias results in growth factor independence and enhanced tumorigenicity. Oncogene. 12: 1405-1415, 1996.
31. Muszynski KW, Ohashi T, Hanson C, Ruscetti SK. Both the Polycythemia- and Anemia-Inducing Strains of Friend Spleen Focus-Forming Virus Induce Constitutive Activation of the Raf-1/Mitogen-Activated Protein Kinase Signal Transduction Pathway. J Virol 72: 919-925, 1998.
32. Berman K, Cobb M H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrinology Rev 2: 153-183, 2001.
33. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 410: 37-40, 2001.
34. Yoon S, Soger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24: 21-44, 2006.
35. Milella M, Kornblau SM, Andreeff M. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol 7: 160-190, 2003.
36. Gerlach N, Schimmer S, Weiss S, Kalinke U, Dittmer U. Effects of type 1 interferons on Friend retrovirus infection. J Virol 80: 3438-3444, 2006.